TaperCommunity
A patient comes in after years on an antidepressant, ready to stop, and their clinician hands them a two-week taper and wishes them luck.
That scenario plays out every day, and it fails patients in a specific, documented way. The field has gotten reasonably good at starting medications. It has not gotten good at stopping them. Standard practice still treats discontinuation as a minor administrative task: cut the dose in half for a couple of weeks, then stop. For some medications, that works fine. For others, it causes suffering that can last months or years, and which clinicians then misread as relapse.
The distinction matters enormously, because misreading withdrawal as relapse leads directly to restarting a drug the patient no longer needed. That is not a theoretical concern. It is a well-documented pattern in the literature.
A 2024 synthesis published in Molecular Psychiatry by Vinkers and colleagues reviewed discontinuation evidence across six major psychotropic classes: antidepressants, antipsychotics, benzodiazepines, mood stabilizers, opioids, and stimulants. Their conclusion was blunt: evidence-based guidance on rational discontinuation is scarce, and what guidance exists is poorly implemented in clinical practice.
So which medications are actually the hardest to stop, and why?
Benzodiazepines are arguably the most physiologically dangerous class to discontinue abruptly. The mechanism is well understood: prolonged use causes downregulation of GABA-A receptors, so removing the drug suddenly leaves the central nervous system in a hyperexcitable state. Seizures and severe autonomic instability are real risks, not rare edge cases. The Ashton Manual, developed by Dr. Heather Ashton over decades of clinical work with dependent patients, remains one of the most detailed practical guides to benzodiazepine tapering available. It recommends slow, flexible tapers that can take months to years for long-term users.
Antidepressants, particularly SNRIs like venlafaxine and desvenlafaxine, sit close behind. The short half-life of venlafaxine means plasma levels drop quickly when doses are missed or reduced, producing what has been clinically sanitized as "discontinuation syndrome." Patients know it as brain zaps, electric shock sensations moving through the head and limbs, dizziness, nausea, profound irritability, and a sense of depersonalization that can be genuinely frightening. Online communities document this in real time; the r/Psychiatry thread by user BladeFatale asking clinicians to rank medications by discontinuation difficulty drew significant engagement precisely because clinicians themselves recognize the hierarchy of difficulty, even if guidelines have been slow to formalize it.
The hyperbolic tapering framework developed by Horowitz and Taylor, published in Psychiatry Research in 2019, explains why standard dose-halving tapers fail so many patients. Receptor occupancy does not scale linearly with dose. At higher doses, cutting by 50% produces a relatively small change in receptor occupancy. At lower doses, the same absolute cut produces a massive neurological shift. This means the last few milligrams of an antidepressant are pharmacologically the hardest to remove, and yet standard tapering schedules spend the least time there. The Maudsley Deprescribing Guidelines formalized this into clinical recommendations: reductions of roughly 10% of the current dose at each step, with steps no faster than every two to four weeks, adjusted to the individual.
Antipsychotics present a different and underappreciated discontinuation challenge. A 2022 survey by John Read, published in Addictive Behaviors Reports, collected experiences from 585 antipsychotic users across 29 countries who had tried to stop taking these medications. Seventy-two percent reported classical withdrawal effects including nausea, tremors, anxiety, agitation, and headaches. Of those, 52% rated the effects as severe. Perhaps most striking: none recalled being told anything about withdrawal effects by their prescriber. Not a single person. A 2025 review by Moncrieff and Horowitz in Schizophrenia laid out the biological basis for this, noting that antipsychotics cause significant dopamine receptor upregulation, and that abrupt discontinuation can produce rebound dopamine supersensitivity, which can trigger psychosis that looks clinically identical to relapse. Their proposed tapering approach mirrors the hyperbolic model: reductions of 5 to 10% of the most recent dose, roughly monthly, for patients on long-term treatment.
Mood stabilizers like lithium and valproate carry their own discontinuation risks. Rapid lithium discontinuation is associated with rebound mania at rates substantially higher than the natural course of the illness would predict, a phenomenon documented in multiple cohort studies. This is not the underlying bipolar disorder reasserting itself on its natural timeline. It is a pharmacologically driven rebound that can be severe and can occur even in patients who had been stable for years.
Stimulants used for ADHD, and Z-drugs used for sleep, generally carry lower acute safety risks on discontinuation, though rebound effects, particularly insomnia rebound after Z-drug cessation, can be clinically significant and push patients back onto medications they were trying to leave.
What makes this hard in practice is not a lack of knowledge. The evidence is there. What is hard is time, and the absence of clinical infrastructure for slow tapers.
A patient tapered over six to twelve months needs multiple appointments, flexible dose adjustments, and a clinician willing to slow down or pause when symptoms flare. Most psychiatric practices are not structured for this. Patients get a taper schedule and a follow-up in six weeks. When that fails, the interpretation is often "the patient still needs the medication" rather than "the taper was too fast."
The r/Psychiatry thread by user facultativo comparing withdrawal across antidepressants and antipsychotics generated substantial clinical discussion precisely because the hierarchy is real and practicing clinicians navigate it without formal guidance. The clinical experience is there. The guidelines have not caught up.
The first step is honest risk stratification before initiating any taper. Duration of use matters. Longer exposure generally means more neuroadaptation and a harder withdrawal. Dose matters. Higher doses require more time. The specific drug matters: venlafaxine and paroxetine warrant more caution than fluoxetine, which has a long half-life that provides a degree of self-tapering.
For antidepressants and antipsychotics, the hyperbolic tapering model is the current best practice. This means using liquid formulations, small-dose tablets, or compounded preparations to achieve the small reductions required in the lower dose ranges. It means educating patients at the outset that the last portion of the taper is typically the hardest, not the easiest, so they are not caught off guard.
For benzodiazepines, many patients benefit from switching to a longer-acting equivalent such as diazepam before tapering, a strategy the Ashton Manual details extensively.
Across all classes, withdrawal symptoms should be treated as a clinical signal requiring a pause or slower reduction rate, not as evidence that the patient is incapable of stopping the medication.
Getting patients onto psychiatric medication is only half the clinical job. The other half, done well, requires recognizing that the brain adapts to these drugs in ways that make stopping genuinely difficult, that this difficulty varies substantially by drug class and individual history, and that the standard two-week taper is a clinical failure dressed up as a protocol. The evidence for slower, hyperbolic tapering is solid. The case studies of prolonged suffering from poorly managed discontinuation are extensive and consistent. Patients deserve clinicians who know the difference between withdrawal and relapse, who plan for a long taper from the moment a medication is started, and who treat the process of stopping a drug with the same care they brought to starting it.